Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Tributylmethylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GRK2 | P25098 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tributylmethylammonium SCHEMBL1627727 | 0.92 | TP53 (0.41) | SLC22A1CA1CA2DNM1TP53 | |
| SCHEMBL3190233 | 0.91 | DNM1 (0.48) | SLC22A1CA1CA2DNM1KMT2A | |
| SCHEMBL10968152 | 0.91 | DNM1 (0.48) | SLC22A1CA1CA2DNM1KMT2A | |
| Tributylmethylammonium SCHEMBL28478908 | 0.90 | TP53 (0.40) | SLC22A1CA1CA2DNM1MEN1 | |
| Tributylmethylammonium SCHEMBL268725 | 0.88 | MEN1 (0.39) | SLC22A1CA1CA2DNM1MEN1 | |
| Tetrabuthylammonium SCHEMBL6379094 | 0.86 | SLC22A1 (0.55) | SLC22A1DNM1TP53 | |
| Tributylmethylammonium SCHEMBL1618259 | 0.85 | BBOX1 (0.40) | SLC22A1DNM1MEN1LMNAPOLB | |
| Tetrabuthylammonium SCHEMBL6379089 | 0.84 | SLC22A1 (0.52) | SLC22A1DNM1TP53 | |
| Tributylmethylammonium SCHEMBL27557040 | 0.84 | SLC22A1 (0.35) | SLC22A1CA1CA2DNM1CA12 | |
| Sulfuric Acid SCHEMBL27681657 | 0.83 | DNM1 (0.50) | SLC22A1DNM1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110187010-A1 | SEMICONDUCTOR CLEANING USING SUPERACIDS | SMALL ROBERT J | 2011-08-04 | — | — | US | disclosed |
| US-7923424-B2 | Semiconductor cleaning using superacids | ADVANCED PROCESS TECHNOLOGIES, LLC (US) | 2011-04-12 | — | — | US | disclosed |
| US-7659430-B2 | Method for separating hydrogen chloride and phosgene | BASF AKTIENGESELLSCHAFT (DE) | 2010-02-09 | — | — | US | disclosed |
| US-20070293707-A1 | Method for Separating Hydrogen Chloride and Phosgene | BASF AKTIENGESELLSCHAFT (DE) | 2007-12-20 | — | — | US | disclosed |
| US-20060183248-A1 | Semiconductor cleaning using superacids | ADVANCED PROCESS TECHNOLOGIES, LLC | 2006-08-17 | — | — | US | disclosed |
| US-20060183654-A1 | Semiconductor cleaning using ionic liquids | ADVANCED PROCESS TECHNOLOGIES, LLC | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293707-A1 | Method for Separating Hydrogen Chloride and Phosgene | PSPH, SLC9B2, HVCN1 | SLC22A1 776/4885CA1 527/4885CA2 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.